Basic Information
Scenesse
Regulatory Information
EMEA/H/C/002548
Authorised
December 22, 2014
October 23, 2014
10
May 13, 2024
Company Information
Ireland
10 Earlsfort Terrace Dublin 2 D04 T380
CLINUVEL EUROPE LIMITED
Drug Classification
Additional MonitoringExceptional Circumstances
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Overview Summary
This is a summary of the European public assessment report (EPAR) for Scenesse. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Scenesse. For practical information about using Scenesse, patients should read the package leaflet or contact their doctor or pharmacist.